文献速递泌尿男性生殖肿瘤

雄激素信号特征预测mCRPC患者对阿比特龙的反应

A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer.
PubMed 文献 · Eur J Cancer · 2020-01-24

该研究基于II期试验首个模块,在170例转移性去势抵抗性前列腺癌(mCRPC)患者中评估预设雄激素信号特征(核AR过表达、CYP17表达及AR-C/N末端比值≥0.8)与阿比特龙(AA)疗效的关系。48例基线骨髓活检有肿瘤浸润者中,该特征与AA获益显著相关(p<0.001);ERG存在与获益相关(p=0.05),核ARV7阳性及基线骨病灶≥20个与原发耐药相关(p=0.04和p=0.0006)。

要点

  • 预设雄激素信号特征与mCRPC患者从阿比特龙获益显著相关(p<0.001)。
  • 基线骨病灶≥20个与原发耐药相关(p=0.0006)。
  • 核ARV7阳性与原发耐药相关(p=0.04),ERG存在与获益相关(p=0.05)。

核心结论

  • 预设雄激素信号特征高度支持其预测mCRPC最大雄激素阻断策略疗效的价值,进一步验证正在进行。

研究设计与样本

  • II期试验首个模块,阿比特龙醋酸酯(AA)后联合达沙替尼或舒尼替尼。
  • 2011年3月至2015年2月共入组170例患者,44例(26%)对AA原发耐药。
  • 48例基线骨髓活检有肿瘤浸润,基线及进展时采集骨髓活检、骨髓穿刺及血样。

主要发现

  • 治疗前雄激素信号特征与AA获益相关(p<0.001)。
  • ERG存在与获益相关(p=0.05)。
  • 核ARV7存在与原发耐药相关(p=0.04)。
  • 基线骨病灶≥20个与原发耐药相关(p=0.0006)。

关键数值与推荐

  • 预设分子特征包括免疫组化(IHC)检测核雄激素受体(AR)过表达、CYP17表达及AR-C-/N末端表达比值≥0.8。
  • 原发耐药定义为AA治疗后4个月内进展。

临床怎么用

  • 该雄激素信号特征或可用于筛选可能从阿比特龙等最大雄激素阻断策略中获益的mCRPC患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The unmet need for predictive biomarkers emerged from the unpredictable pattern of response to androgen signalling inhibition in metastatic castration-resistant prostate cancer (mCRPC). Here, we report on the testing of a previously identified candidate androgen signalling signature associated with response to androgen signalling inhibition. PATIENTS AND METHODS: We report on the outcome of the first module of a phase II trial on abiraterone acetate (AA) followed by combination with dasatinib or sunitinib. Bone marrow biopsies (BMBs) with matched bone marrow aspirate and blood samples were collected at baseline and upon progression. End-points included assessment of a prespecified molecular signature consisting of nuclear androgen receptor (AR) overexpression, cytochrome P450, family 17, subfamily A, polypeptide 1 (CYP17) expression, and AR-C-/N terminal expression ratio of ≥0.8 by immunohistochemistry (IHC) in patients with benefit versus primary resistance to AA (i.e. progression within 4 months). Tumour markers also included v-ets avian erythroblastosis virus E26 oncogene homologue (ERG), androgen receptor splice variant (ARV7) by IHC and steroids by liquid chromatography-tandem mass spectrometry. RESULTS: Of 170 patients accrued from 03/2011 to 02/2015, 44 (26%) were primary resistant to AA. Forty-eight patients had tumour infiltrated BMB at baseline. Pretreatment androgen signalling signature was linked to benefit from AA (p < 0.001). Presence of ERG was associated with benefit (p = 0.05), whereas nuclear ARV7 presence and 20 or more bone lesions at baseline with primary resistance (p = 0.04 and p = 0.0006, respectively). CONCLUSION: Testing of a prespecified androgen signalling signature was highly supportive of its predictive value in maximal androgen deprivation strategies in mCRPC. Further validation is under way. TRIAL REGISTRATION: ClinicalTrials.gov NCT01254864.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Boukovala M, Spetsieris N, Weldon JA, et al. A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer. Eur J Cancer. 2020. PMID: 31986451. doi:10.1016/j.ejca.2019.12.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。